INMD250117C20000
- 0.05
- 0.000.00%
InMode Newsroom
Needham Maintains InMode(INMD.US) With Hold Rating
Needham Remains a Hold on InMode (INMD)
BTIG Maintains InMode(INMD.US) With Buy Rating, Maintains Target Price $25
Analysts Offer Insights on Healthcare Companies: InMode (INMD) and Sana Biotechnology (SANA)
InMode Lowers 2024 Revenue Guidance; Sets 2025 Revenue Outlook; Shares Slump Pre-Bell
InMode Sees FY24 Adjusted Gross Margin 80%-81%
Express News | InMode Cuts FY24 Revenue Outlook From $410M - $420M To $394M - $394.5M, Est $411.188M
Express News | InMode Expects Q4 Revenue Of $97.0M-$97.5M (Est $114.22M); Preliminary Results Reflect Stronger-than-Expected Headwinds In Aesthetics Industry
InMode to Report Fourth Quarter & Full Year 2024 Financial Results and Hold Conference Call on February 6, 2025, Expects Q4 Revenue Between $97.0M-$97.5M
Is InMode Ltd.'s (NASDAQ:INMD) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
With 57% Institutional Ownership, InMode Ltd. (NASDAQ:INMD) Is a Favorite Amongst the Big Guns
Is There An Opportunity With InMode Ltd.'s (NASDAQ:INMD) 49% Undervaluation?
Why Is InMode Ltd. (INMD) Among the Best Cosmetic Surgery and Aesthetics Stocks to Invest In Now?
InMode Completes Repayment of Silicon Valley Bank Debt
Dr. Luis Macias and Aesthetic MdR Host Esteemed International Visiting Professor Dr. Francisco Gomez Bravo at USC Plastic Surgery
The Returns On Capital At InMode (NASDAQ:INMD) Don't Inspire Confidence
InMode's (NASDAQ:INMD) Earnings Have Declined Over Three Years, Contributing to Shareholders 77% Loss
InMode (NASDAQ:INMD) Might Be Having Difficulty Using Its Capital Effectively
InMode to Present at Upcoming Investor Conferences
We Think You Can Look Beyond InMode's (NASDAQ:INMD) Lackluster Earnings